A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment.

ABSTRACT:

Objective

The objective of this study was to examine clinicians' patient selection and result interpretation of a clinically validated mass spectrometry test measuring amyloid beta and ApoE blood biomarkers combined with patient age (PrecivityAD® blood test) in symptomatic patients evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.

Methods

The Quality Improvement and Clinical Utility PrecivityAD Clinician Survey (QUIP I, ClinicalTrials.gov Identifier: NCT05477056) was a prospective, single-arm cohort study among 366 patients evaluated by neurologists and other cognitive specialists. Participants underwent blood biomarker testing and received an amyloid probability score (APS), indicating the likelihood of a positive result on an amyloid positron emi

SUBMITTER: Monane M 

PROVIDER: S-EPMC10578891 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature